CW August 2001
Volume 10Issue Number 8 August 2001 ISSN 10593802 The NCI Sponsors Study to Determine Improvement in Survival in Lung Cancer PatientsThe National Cancer Institute and the Southwest Oncology Group (SWOG) have announced the start of a Phase III clinical study to evaluate the use of a conventional chemotherapeutic agent, docetaxel (Taxotere®) and a maintenance agent, the experimental ZD1839 (Iressa®) in the treatment of patients with locally advanced non-small cell lung cancer (NSCLC).
Go to Previous Page Go to Next Page Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW August 2001Purchase Downloadable Full-text PDF of Complete Issue: $10.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
